Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.

• Status: Unknown status
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the effect of autologous bone marrow stem cells infusion (ABMSCi) therapy for liver diseases.Treatment group will receive ABMSCi and drugs therapy ,while control group will only receive drugs therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wenzhou Medical University
• Treatments: Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

1. Definite liver diseases (such as viral hepatitis, autoimmune liver diseases, fatty liver diseases, ect);

2. Active bone marrow hyperplasia showed by bone marrow biopsy before ABMSCi;

3. Age between 18 and 60 years;

4. Abnormal liver function.

Exclusion Criteria:

1. Enlisted for liver transplantation

2. Diagnosis of hepatocellular carcinoma or other cancers

3. Other severe medical disease, and acute infection

4. pregnant or nursing females,co-infections with HIV ,serious bacterial infection

5. other vital organ or system dysfunction

6. with severe complications of liver cirrhosis

7. hematological disorder